{"schema_version":"secwatch.filing_event.v1","accession":"0001690585-26-000021","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.742394+00:00","generated_at":"2026-05-14T23:26:32.238484+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dianthus Q1 net loss $40.8M; cash $1.2B; claseprubart and DNTH212 advance","bullets":["Net loss $40.8M ($0.85/share) vs $29.5M ($0.82) in Q1 2025; R&D spend $34.5M up from $27.0M.","Cash $1.2B at March 31, including $719M gross from March public offering; runway into 2030.","Claseprubart: Early GO in CAPTIVATE CIDP trial; Phase 3 gMG trial mid-2026 with top-line 2H'28.","DNTH212: Priority indications SjD, SLE, DM; Phase 1 healthy volunteer data expected 2H'26.","Orphan Drug Designation for claseprubart in MG; FDA agreed to remove ANA screening and DIL reclassification."],"urls":{"canonical":"https://secwatch.observer/filing/0001690585-26-000021","json":"https://secwatch.observer/filing/0001690585-26-000021.json","markdown":"https://secwatch.observer/filing/0001690585-26-000021.md","text":"https://secwatch.observer/filing/0001690585-26-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000169058526000021/0001690585-26-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000169058526000021/dnth-20260505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:26:32.238484+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ecc0be623e5614bf7e5ebdad5b9efe5785593674","claim":"Dianthus Therapeutics, Inc. /DE/ reported financial results for the first quarter ending March 31, 2026.","evidence_excerpt":"On May 5, 2026, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000169058526000021/0001690585-26-000021-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ending March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}